This page is intended to provide scientific information to scientific research professionals. Gossamer Bio’s drug candidates are investigational medicines and have not been approved by The United States Food and Drug Administration (USFDA), Health Canada, the European Medicines Agency (EMA), nor any other regulatory agency.
Seralutinib (GB002)
Real-World Referral Patterns of PAH Patients to PHA-Accredited Comprehensive Care Centers in the State of Texas 2019-2020
CHEST - October 2022
Quantitative Immunohistochemistry of PDGFRα, PDGFRβ, c-KIT and CSF1R in Human PAH Lung Samples
ERS - September 2022
See More
GB7208
A CNS-Penetrant BTK Inhibitor Modulates Multiple Pathogenic Pathways Implicated in Multiple Sclerosis
ACTRIMS - Feb 2023
GB7208 is a CNS-Penetrant BTK Inhibitor Demonstrating Potent Activity on Pathogenic Pathways Implicated in Multiple Sclerosis
ECTRIMS1 – October 2022
See More
GB5121
GB5121 is an Oral, CNS-Penetrant, Potent and Selective BTK Inhibitor for the Treatment of CNS Malignancies
SNO - November 2022
GB5121 is a Novel, Highly Potent and Selective CNS-Penetrant BTK Inhibitor for CNS Malignancies
SNOASCO - Aug 2022
See More
Discovery Programs
Diacylglycerol Kinase Alpha and Zeta Dual Inhibitors Enhance T Cell Responses and Promote Robust and Durable Anti-Tumor T Cell Immunity
SITC - November 2022
See More